An observational study in Coronary Artery Disease, Bypass Graft Stenosis and Dyslipidemias, sponsored by Chinese University of Hong Kong. Withdrawn at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Chinese University of Hong Kong · Observational
This single-centre cross-sectional study aims to ascertain the impact of dyslipidemia on long-term graft patency after coronary artery bypass grafting (CABG).
All consecutive patients who underwent CABG from 1st January 2007 to 31st December 2008 at the Prince of Wales Hospital were eligible for entry.
Graft patency will be determined by computed tomography coronary angiogram. The severity of stenosis will be classified by the Fitzgibbon classification system.
The levels of individual lipid profile subcomponents, namely LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol and triglycerides (TG) will be obtained. A plot of lipid profile subcomponent measurements against time will be compiled and the area under the curve is calculated to estimate gross exposure after CABG. Average lipid exposure is calculated by dividing the gross exposure by the number of days lapsed between the first and last lipid profile measurements.
The association between average cholesterol target attainment and graft patency will then be determined.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
Browse Coronary Artery Disease studies →Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All living consecutive patients on record who underwent isolated coronary artery bypass graft surgery in 2007 and 2008 at Prince of Wales Hospital were eligible for participation. Patients were excluded if they were at high risk of contrast nephropathy.
Exclusion Criteria:
Preparation * Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute * Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning * 18G angiocath at a large antecubital vein for intravenous contrast injection Scanning procedure Contrast CT angiogram (Retrospective gating) * Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser * Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100 * Scanning coverage: From the thoracic inlet to diaphragm
Graft patency
Graft patency as assessed by computed tomographic coronary angiogram, using Fitzgibbon classification
Time frame: Immediately after CTCA
Actuarial cardiac events
Events attributable to cardiac causes as adjudicated by the investigators, including congestive heart failure, ischaemic cardiomyopathy, myocardial infarction, ventricular arrhythmias, recurrent angina
Time frame: Immediately after CTCA
Plan to share: Undecided
This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong